This question has been answered by the relevant Government Department.
To ask Her Majesty's Government what assessment they have made of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee's recommendation to revoke the marketing authorisation of ulipristal acetate as a treatment for uterine fibroids; and whether they intend to implement the same revocation in the UK.
Legend for business item text
† Item that is new or altered.
[I] Indicates that the member concerned has a relevant registered interest.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.
Member's Registered Interests
There are no interests to show.